Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluticasone propionate + vilanterol
- Development stage
- Phase 4
- Lead developer
- GSK
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Inhalation
01
Overview
Fluticasone propionate + vilanterol is a fixed-dose combination inhalation medication used for the long-term maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is indicated when symptoms are not adequately controlled with other asthma medications or when more than one daily medicine is required. Fluticasone propionate is an inhaled corticosteroid that reduces inflammation in the airways by inhibiting the release of inflammatory mediators from certain lung cells. Vilanterol is a long-acting beta2-adrenergic agonist (LABA) bronchodilator that relaxes airway smooth muscle, leading to bronchodilation and improved airflow. The combination improves lung function, reduces exacerbations, and helps control symptoms but does not treat acute attacks[1][2][3].
- Brand names
- Breo Ellipta
- Other names
- fluticasone and vilanterolfluticasone/vilanterol
02
Targets
ADRB2 (β2)GR (Glucocorticoid receptor)ABCB1 (P-glycoprotein)
Beyond the preview
Go deeper on fluticasone propionate + vilanterol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluticasone propionate + vilanterol.